Login / Signup

Immunotherapies and COVID-19 mortality: a multidisciplinary open data analysis based on FDA's Adverse Event Reporting System.

Maximilian PistorAndreas G F HoepnerYanan LinSimon JungClaudio L BassettiAndrew ChanAnke SalmenRobert Hoepner
Published in: Annals of the rheumatic diseases (2021)
Keyphrases
  • data analysis
  • coronavirus disease
  • adverse drug
  • sars cov
  • minimally invasive
  • cardiovascular events
  • risk factors
  • quality improvement
  • emergency department
  • coronary artery disease